Viewing Study NCT00819169

Home

Certify Doc

Genes

Clinical Trials

CompTox

DrugMatrix

Open Targets

Products

Support

Bugs

Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug

Ignite Creation Date: 2025-12-24 @ 11:08 PM

Ignite Modification Date: 2026-01-01 @ 5:34 PM

Study NCT ID: NCT00819169

Status: TERMINATED

Last Update Posted: 2024-08-20

First Post: 2009-01-06

Is NOT Gene Therapy: True

Has Adverse Events: True

Brief Title: QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors

Sponsor: NantCell, Inc.

Organization:

Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Study Overview

Official Title: A Phase 1b/2 Open Label, Dose Escalation Study of AMG 655 in Combination With AMG 479 in Subjects With Advanced, Refractory Solid Tumors

Status: TERMINATED

Status Verified Date: 2024-07

Last Known Status: None

Delayed Posting: No

If Stopped, Why?: Sponsor decision - subjects rolled over to protocol 20101116

Has Expanded Access: False

If Expanded Access, NCT#: N/A

Has Expanded Access, NCT# Status: N/A

Acronym: None

Brief Summary: This is a multi-center, 2-part phase 1b/2 study of AMG 655 in combination with AMG 479 to be conducted in the United States and Spain.

Part 1 is a dose escalation segment to identify a dose of AMG 655 in combination with AMG 479 that is safe and tolerable.

Part 2 will evaluate the safety and estimate the efficacy of AMG 655 at the dose selected in Part 1 in combination with AMG 479 for the treatment of patients with advanced NSCLC (non-squamous histology; squamous histology), CRC, pancreatic cancer, ovarian cancer, and sarcoma.

Detailed Description: None

Study Oversight

Has Oversight DMC:

Is a FDA Regulated Drug?:

Is a FDA Regulated Device?:

Is an Unapproved Device?:

Is a PPSD?:

Is a US Export?:

Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID	Type	Domain	Link	View

QUILT-3.026	OTHER	NantCell, Inc.		View